6-chloro-2-(1-piperazinyl)pyrazine
Showing 1 - 25 of >10,000
Thyroid Cancer, Anaplastic Thyroid Cancer, Undifferentiated Thyroid Cancer Trial in Stanford (Abemaciclib)
Active, not recruiting
- Thyroid Cancer
- +2 more
-
Stanford, CaliforniaStanford University
Nov 8, 2022
Recurrent Acute Myeloid Leukemia Trial in Duarte (Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate)
Withdrawn
- Recurrent Acute Myeloid Leukemia
- Bosutinib Monohydrate
- +6 more
-
Duarte, CaliforniaCity of Hope Meidcal Center
Jun 7, 2022
Diabetes Type 2 With Proteinuria, Diabetes, Type 2, Diabetes Trial (drug, device, diagnostic test, behavioral)
Not yet recruiting
- Diabetes Mellitus Type 2 With Proteinuria
- +12 more
- Empagliflozin 10 MG
- +6 more
- (no location specified)
Oct 17, 2023
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (Palbociclib, Tazemetostat,
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Palbociclib
- +4 more
-
Philadelphia, PennsylvaniaThomas Jefferson University Hospital
Jan 13, 2023
Dentin Sensitivity, Molar Incisor Hypomineralization Trial in Brescia (CPP-ACPF, PBMT, CPP-ACPF+PBMT)
Recruiting
- Dentin Sensitivity
- Molar Incisor Hypomineralization
- CPP-ACPF
- +2 more
-
Brescia, ItalyDental Clinic
Jan 21, 2023
Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in New Haven (procedure, drug, biological)
Recruiting
- Metastatic Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm
- Biopsy
- +2 more
-
Boston, Massachusetts
- +2 more
Jan 25, 2023
Malignant Female Reproductive System Tumor, Malignant Solid Tumor, Recurrent Malignant Female Reproductive System Tumor Trial
Not yet recruiting
- Malignant Female Reproductive System Neoplasm
- +3 more
- Biopsy
- +7 more
- (no location specified)
Nov 9, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
-
Duarte, California
- +2 more
Oct 7, 2022
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection Trial in Buffalo (Clindamycin, Diary, Ertapenem)
Recruiting
- Bladder Carcinoma
- +2 more
- Clindamycin
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
May 3, 2022
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- (no location specified)
Jun 2, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma Trial in
Not yet recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +14 more
- Biopsy
- +25 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 12, 2022
Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,
Recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Malignant Supratentorial Tumor, Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Houston (Lonafarnib, Temozolomide)
Active, not recruiting
- Malignant Supratentorial Neoplasm
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2021
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous
Recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 6, 2022
Tooth Demineralization Trial (Sugar free gum without CPP-ACP, Sugar free gum with CPP-ACP)
Not yet recruiting
- Tooth Demineralization
- Sugar free gum without CPP-ACP
- Sugar free gum with CPP-ACP
- (no location specified)
Oct 15, 2021
Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma Trial (Computed Tomography, Magnetic Resonance
Not yet recruiting
- Metastatic Leiomyosarcoma
- +5 more
- Computed Tomography
- +3 more
- (no location specified)
Feb 2, 2023
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial (Biopsy, Biospecimen
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
- (no location specified)
Jan 14, 2023
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV
Recruiting
- Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
- +2 more
- Duvelisib
- +2 more
-
Phoenix, Arizona
- +11 more
Aug 6, 2022
Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,
Recruiting
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Scottsdale, Arizona
- +2 more
Jun 1, 2022
Neuroendocrine Tumor Trial in United States (Lutetium Lu 177 Dotatate, Peposertib)
Recruiting
- Neuroendocrine Neoplasm
- Biospecimen Collection
- +4 more
-
Duarte, California
- +3 more
Jan 12, 2023
Substance Use Disorders, Parent-Child Relations, Parent Child Abuse Trial in Philadelphia (MIO-CPP, CPP-only)
Enrolling by invitation
- Substance Use Disorders
- +2 more
- MIO-CPP
- CPP-only
-
Philadelphia, PennsylvaniaRoberts Center for Pediatric Research
Mar 23, 2022
Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in United States
Recruiting
- Advanced Colorectal Carcinoma
- +26 more
- Irinotecan
- +2 more
-
Tampa, Florida
- +3 more
Jun 22, 2022
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in
Recruiting
- Fallopian Tube Carcinosarcoma
- +28 more
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
-
Aurora, Colorado
- +7 more
Sep 2, 2022
Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer
Recruiting
- Locally Advanced Pancreatic Adenocarcinoma
- +6 more
- Hypofractionated Radiation Therapy
- +2 more
-
Duarte, California
- +29 more
Apr 2, 2022